Skip to main content
Download PDF

The value of plasma pro-enkephalin and adrenomedullin for the prediction of sepsis-associated acute kidney injury in critically ill patients

Critical Care volume 24, Article number: 162 (2020) Cite this article

Kidney function is commonly affected by sepsis, which is one of the most prominent causes of acute kidney injury (AKI) [1]. Seeking early, reliable biomarkers for the detection of AKI in critically ill patients with sepsis, it is of great importance to conduct successful interventions and reduce adverse outcomes.

Pro-enkephalin is considered as a reliable alternative marker of enkephalin, which is an endogenous opioid peptide and may be associated with decreased renal function [2]. Adrenomedullin, a protein from the calcitonin family, has been reported to increase significantly in patients with sepsis [3]. We prospectively evaluated the predictive value of plasma pro-enkephalin and adrenomedullin (Shuwen Biotech Co. Ltd, China) levels for septic AKI compared to other candidate biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), cystatin-C, kidney injury molecule 1 (KIM-1), and interleukin 18 (IL-18)) (Boster Biological Technology co. Ltd, China).

Forty-two septic patients (age ≥ 18) in the intensive care unit were included in the final analysis. Blood samples were collected from a peripheral vein or central venous within 24 h after the patient was diagnosed with sepsis based on sepsis-3 criteria [4]. According to the 2013 KDIGO standard, patients were divided into one of the cohorts and staged based on the worst serum creatinine and/or the lowest urine output [5].

Among the participants, sixteen patients subsequently suffered from AKI, five of whom were in stage 1, eleven were in stage 3, and no patients were in stage 2. A significant difference of plasma pro-enkephalin concentration exists in the septic AKI group and sepsis group (median 229.2 (93.62–341.2) vs 64.71 (49.23–90.87) pmol/L, P < 0.0001). In addition, patients in AKI stage 3 had higher plasma pro-enkephalin (292.94 ± 140.18 vs 125.06 ± 65.82 pg/mL) levels than those in AKI stage 1. The plasma adrenomedullin concentration in the septic AKI group was significantly higher than that in the sepsis group (median 164.69 (118.07–193.52) vs 76.5 (48.66–132.31) pg/mL, P = 0.0229). There was no significant difference in plasma NGAL (median 2.37(2.21–2.37) vs 2.25(1.96–3.32) pg/mL, P = 0.9631), cystatin-C (mean 28.85 ± 7.25 vs 31.24 ± 14.72 pg/mL, P = 0.7353), KIM-1 (median 408.21(0.91–666.5) vs 96.22(0.26–260.12) pg/mL, P = 0.1795), and IL-18 (median 136.1(133.36–524.19) vs 184.71(101.84–665.98) pg/mL, P = 0.0229) existed in septic patients with and without AKI.

The receiver operating characteristic analysis for the assessment of the diagnostic accuracy of pro-enkephalin and adrenomedullin in the prediction of AKI in septic patients showed significant predictive value for both biomarkers, with area under curve (AUC) of 0.884 (95% CI, 0.738–0.965) and 0.731 (95% CI, 0.560–0.863), respectively (Fig. 1). Pro-enkephalin had a sensitivity of 60.87% and specificity of 100% at the cutoff value of 66.97 pmol/L, while adrenomedullin had a sensitivity and specificity of 75% and 76.92%, respectively, at a cutoff value of 110.44 pg/mL. The combination of the two biomarkers revealed the highest discrimination and had an AUC of 0.890 (95% CI, 0.740–0.969) as well as a sensitivity of 92.31% and a specificity of 69.57%. The pro-enkephalin and adrenomedullin are promising biomarkers for physicians to promptly assess the presence and severity of AKI at an early stage, which will make contribution to start adequate treatment immediately and avoid worse outcome. The limitations of our study include the limited sample size as well as the certain biomarkers, such as NGAL, KIM-1, and IL-18, lacking the detection data of urine specimens which may differ from the diagnostic accuracy of blood specimens.

Fig. 1
figure 1

The receiver operating characteristic curve showing the diagnostic power of pro-enkephalin, adrenomedullin, and the combination of pro-enkephalin and adrenomedullin for the estimation of acute kidney injury in septic patients. pro-ENK, pro-enkephalin; ADM, adrenomedullin

Full size image

Availability of data and materials

Data are available on request.

References

  1. Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010;77(6):527–35.

    Article  CAS  Google Scholar 

  2. Arbit B, Marston N, Shah K, Lee EL, Aramin H, Clopton P, et al. Prognostic usefulness of proenkephalin in stable ambulatory patients with heart failure. Am J Cardiol. 2016;117(8):1310–4.

    Article  CAS  Google Scholar 

  3. Bernal-Morell E, García-Villalba E, Vera MDC, Medina B, Martinez M, Callejo V, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Inf Secur. 2018;76(3):249–57.

    Google Scholar 

  4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.

    Article  CAS  Google Scholar 

  5. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

KJY was funded by the National Natural Science Foundation of China (No.81571871 and 81770276) and Nn10 program. CSW was supported by Distinguished Young Scholars Fund of Harbin Medical University Cancer Hospital, the Yuweihan Fund for Distinguished Young Scholars of Harbin Medical University, Harbin Science and Technology Innovation Scholar Fund (2017RAXXJ087), and Heilongjiang Province Postdoctoral Research Fund. The funding sources were not involved in the design of the study; in the collection, analysis, and interpretation of data; or in writing the manuscript.

Author information

Author notes

  1. Ruijin Liu, Xiaoya Zheng, and Hongliang Wang contributed equally.

Authors and Affiliations

  1. Department of Critical Care Medicine, Harbin Medical University Cancer Hospital, No. 150 Haping Rd., Nangang District, Harbin, 150081, China

    Ruijin Liu, Xiaoya Zheng, Sicong Wang & Changsong Wang

  2. Department of Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    Hongliang Wang

  3. Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Rd., Nangang District, Harbin, 150001, China

    Kaijiang Yu

Authors
  1. Ruijin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoya Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongliang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sicong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaijiang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changsong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LRJ and WSC conducted sample collection and biochemical analysis. ZXY and WHL were involved in the data collection and statistical analysis. LRJ and ZXY contributed to data interpretation and drafting of the manuscript. WCS and YKJ contributed to study design, manuscript revision, and providing facilities. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Kaijiang Yu or Changsong Wang.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the ethical committee of the Second Affiliated Hospital of Harbin Medical University (Harbin, China) (KY2018-292). Written informed consent was obtained from all patients or their surrogates.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, R., Zheng, X., Wang, H. et al. The value of plasma pro-enkephalin and adrenomedullin for the prediction of sepsis-associated acute kidney injury in critically ill patients. Crit Care 24, 162 (2020). https://doi.org/10.1186/s13054-020-02887-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-020-02887-6

Critical Care

ISSN: 1364-8535